Original Article

Decline of Hepatitis B Virus in Iranian Blood Donors in the Last Decade (2001-2010)

Mahmoodian-Shooshtari M1*, Sharifi Z2, Mousavi SE2, Ahmadi-Teymourloyee SA3

1. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran.
2. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences.
3. Department of Health Services Management, School of Health Management and Information Sciences, Tehran University of Medical Sciences.

Abstract

Background and Aims: This study was the trends of Hepatitis B infection among Iranian blood donors which was analyzed in a period of 10 years.

Materials and Methods: In a period of 10 years, from 2001 through 2010, a total of 16,264,830 donations from 30 regional and 35 local blood services were screened. All blood samples were tested for Hepatitis B surface antigen (HBs Ag) by commercial available kits. Sistan-Baluchestan (S&B) province representing a high prevalence and Fars province was a low prevalence area. For assessing frequency of infection, the prevalence of HBs Ag per 100,000 donations and 95% confidential intervals (95% CIs) was calculated. Statistical analysis was conducted using chi-square test and considered significant if P value was <0.05.

Results: The prevalence rates of HBs Ag dramatically declined from 1.23% in 2001 to 0.25% in 2010 in Iran. In S&B province HBs Ag prevalence decreased from 3.29% in 2001 to 0.66% in 2010 and in Fars province, the rate of HBs Ag decreased from 0.82% in 2001 to 0.12% in 2010. In this period, the number of donation progressively increased from 1361321 donation in 2001 to 1889851 donation in 2010, P v <0.00001. The number of volunteer donations increased from 92% in 2001 to 100% in 2010.

Conclusion: The findings indicated that an appropriate implementation of Iranian Blood Transfusion Organization (IBTO) programs such as the selection of blood donors/ donor recruitment, increasing non-remunerated repeat donors, routine screening for blood borne viruses, replacement donation exclusion, and implementation of automation are being performed.

Keywords: Hepatitis B virus; Blood Donation; Prevalence; Iranian Blood Transfusion Organization (IBTO)

Introduction

Hepatitis B virus (HBV) infection is an important public health problem and is a very common cause of chronic liver disease worldwide (1). Approximately 2 billion people in the world have been infected by HBV, about 400 million have chronic infection and 600,000 die each year from HBV related liver disease (1). At least 35% of Iranian population have been exposed to HBV and 3% are chronic carriers (2). From 1970 with the introduction of Hepatitis B surface antigen (HBs Ag) testing, the risk of post transfusion Hepatitis B virus has steadily decreased (3). An appropriate implementation
of Iranian Blood Transfusion Organization (IBTO) protocols such as selection of blood donors/ donor recruitment, increasing non-remunerated repeat donors, routine screening for blood borne viruses, improving laboratory tests, replacement donation exclusion, implementation of automation and finally appropriate use of blood and blood components have all resulted in reduction of risk of virus infection in recipients (4, 5). Since the foundation of IBTO in 1974, every single unit of blood is tested for HBs Ag as well as anti HIV, HIV Ag, and anti HCV according to the set standards to maximize safety of the blood.

However, assessment of the potential risk of transfusion-transmitted infectious disease such as HBV and the safety of the blood supply can be estimated by monitoring the prevalence of the serologic markers of the infectious diseases in screening tests. In the present study, we assessed changes in the rates of HBV infection among Iranian blood donors in the period of 2001-2010 in the Blood Transfusion Research Center, and the Institute for Research and Education in Transfusion Medicine. In addition, the rate of HBs Ag infection was studied in two provinces for the purpose of comparison, one with high and the other with low prevalence areas. The results indicated the effectiveness of the safety measures employed during this period.

**Methods**

During a period of 10 years, from 2001 through 2010, a total of 16,264,830 voluntary and replacement blood donors from 30 regional and 35 local blood services were screened. The blood donors were selected using a uniform questionnaire, and physical examination for blood borne viruses such as tattooing, sight of illegal drugs injections, skin lesion, history of jaundice and behavioral habits. The donors were aged between 18 and 65 years and about 77% of them were men. All blood samples were tested for HBs Ag using commercial available kits, such as Enzygnost HBs Ag 5.0 (DADE BEHRING), Enzygnost HBs Ag 6.0 (Siemens), Monalisa Ag HBs plus (BIO-RAD), and ETI-MAK-4 (Dia-Sorin). The sensitivity of all kits was similar according to the results of Boston Biomedica Inc. panels (BBI). The HBs Ag prevalence per 100,000 donations/years and (95% CIs) confidence interval was calculated. Statistical analysis was conducted using chi-square test and considered significant if P value was <0.05.

**Results**

The overall prevalence rates of HBs Ag decreased from 1.23% in 2001 to 0.25% in 2010 in Iran (Table 1). In S&B province HBs Ag prevalence decreased from 3.29% in 2001 to 0.66% in 2010 and in Fars province, the rate of HBs Ag decreased from 0.82% in 2001 to 0.12% in 2010 (Table 1). Also in this period, the number of donations progressively increased from 1361321 donations in 2001 to 1889851 donation in 2010, P v <0.00001 (Figure 1). The number of volunteer donations increased from 92% in 2001 to 100% in 2010. Since 2007, all blood donations were voluntary. The number of volunteer donation in Iran from 2001 through 2010 is shown in Table 2.

**Discussion**

The prevalence of chronic HBV infection varies geographically, from high (>8%), intermediate (2-7%) to low (<2%) (6). In the Middle East, countries are classified as having low endemicity (< 2%), intermediate endemicity (2%–5%), or high endemicity (> 5%) of infection (7). According to the international classification, Iran was classified as having low endemicity for HBV infection (8). There is established data confirming that the prevalence of HIV, hepatitis viruses, and other blood borne viruses are lowest among volunteer blood donors (4). Surveys of viral markers in the donor population from well-developed blood systems, such as Iranian Blood Transfusion Organization (IBTO), demonstrated that donor selection procedures
Decline of Hepatitis B virus in Iranian Blood Donors …

Table 1. HBs Ag prevalence among blood donations in the whole country (30 provinces), and also in high prevalence area (S&B) and low prevalence area (Fars) during 2001-2010.

<table>
<thead>
<tr>
<th>Year</th>
<th>Iran Units donated/year</th>
<th>S &amp; B Province</th>
<th>Fars Province</th>
<th>Iran HBs Ag + units no. (%)</th>
<th>High Prevalence area (S &amp; B)</th>
<th>Low Prevalence area</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>1361321</td>
<td>58866</td>
<td>113795</td>
<td>16760 (1.23)</td>
<td>1934 (3.29)</td>
<td>928 (0.82)</td>
</tr>
<tr>
<td>2002</td>
<td>1448149</td>
<td>63424</td>
<td>125251</td>
<td>17447 (1.20)</td>
<td>1646 (2.60)</td>
<td>885 (0.71)</td>
</tr>
<tr>
<td>2003</td>
<td>1489935</td>
<td>63302</td>
<td>131751</td>
<td>11956 (0.80)</td>
<td>1074 (1.69)</td>
<td>805 (0.61)</td>
</tr>
<tr>
<td>2004</td>
<td>1494282</td>
<td>60781</td>
<td>138073</td>
<td>10866 (0.73)</td>
<td>1267 (2.08)</td>
<td>763 (0.55)</td>
</tr>
<tr>
<td>2005</td>
<td>1603149</td>
<td>62988</td>
<td>145452</td>
<td>9731 (0.61)</td>
<td>1099 (1.74)</td>
<td>704 (0.48)</td>
</tr>
<tr>
<td>2006</td>
<td>1667412</td>
<td>62297</td>
<td>142563</td>
<td>8607 (0.52)</td>
<td>858 (1.38)</td>
<td>497 (0.35)</td>
</tr>
<tr>
<td>2007</td>
<td>1735008</td>
<td>56057</td>
<td>148014</td>
<td>7092 (0.41)</td>
<td>644 (1.15)</td>
<td>503 (0.34)</td>
</tr>
<tr>
<td>2008</td>
<td>1784246</td>
<td>58515</td>
<td>147953</td>
<td>6406 (0.36)</td>
<td>636 (1.08)</td>
<td>374 (0.25)</td>
</tr>
<tr>
<td>2009</td>
<td>1791477</td>
<td>55223</td>
<td>148345</td>
<td>5337 (0.30)</td>
<td>432 (0.72)</td>
<td>347 (0.23)</td>
</tr>
<tr>
<td>2010</td>
<td>1889851</td>
<td>63257</td>
<td>151924</td>
<td>4663 (0.25)</td>
<td>421 (0.66)</td>
<td>185 (0.12)</td>
</tr>
<tr>
<td>Total</td>
<td>16264830</td>
<td>604710</td>
<td>1393121</td>
<td>98865 (0.64)</td>
<td>10011 (1.65)</td>
<td>5991 (0.4)</td>
</tr>
</tbody>
</table>

result in marker prevalence and incidences, which are significantly lower than that of the general population (4).

Results of this study demonstrated that the prevalence rates of HBs Ag declined from 1.23% in 2001 to 0.25% in 2010 in blood donors in Iran. In S&B province HBs Ag prevalence decreased from 3.29% in 2001 to 0.66% in 2010 and in Fars province, the rate of HBs Ag decreased from 0.82% in 2001 to 0.12% in 2010 (Table 1). A difference in prevalence exists among different provinces and reflecting geographical and social differences. Also, the number of volunteer donations increased from 92% in 2001 to 100% in 2010. Since 2007 all blood donations were voluntary (Table 2).

Our findings are matched with previous reports. In one study, a total of 14599783 blood donation were collected and screened for HBs Ag. The overall HBs Ag prevalence rates declined from 1.79% in 1998 to 0.41% in 2007 (9). Another study also showed that the prevalence of HBV, HCV, and HIV decreased during the 4-year study from 2004 through 2007 in the blood donation (10). The overall prevalence was 0.56% for HBV, 0.004% for HIV, and 0.13% for HCV (10).

The steady decrease in number of replacement donation from 8% in 2001 to 0% in 2010 plays significant role in the declined prevalence of HBs Ag among donors especially in high prevalence area (S&B) (Table 2). The results of a survey published by the World Health Organization (WHO) have justified that the prevalence of hepatitis viruses which are lowest among volunteer blood donors than that of replacement blood donors and these are significantly lower than that of the general population (4).

In addition, it is reasonable to assume that the decline observed may have been due to the additional safety measures in place. According to the uniform donor deferral criteria at IBTO which is similar to World Health Organization (WHO) recommendation, donors are requested not donate if they had history of yellow jaundice or other liver diseases. Also donors are asked not to donate blood if they had acquired immunodeficiency syndrome (AIDS)-related symptoms, HIV-related risk behaviors and history of viral hepatitis.

Several strategies have suggested to further reduction of prevalence of viruses among blood donors such as centralized blood transfusion system with trained staffs and
better equipment, increasing non-remunerated repeat donors, reduction in replacement donors, the implementation of automation and data registry of blood donors which allows the deferral of volunteers with a history of positive results and routine tests for blood borne viruses.

There are some reports on the prevalence of HBs Ag and anti hepatitis B core antibody in general population in Iran. All reports have confirmed on decreasing changing of HBV. In one study, the prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran was 2.6% and 16.4%, respectively (11). A separate report has also demonstrated that Hepatitis B virus prevalence decreased greatly in Iranian population during the last decade (12). Due to the improvement in general health, general education, the improvement in the people's knowledge about HBV risk factors and implementation of national vaccination program for all neonates and high risk groups, the HBs Ag prevalence rate is changing rapidly. However, the surveillance of Hepatitis B infected individuals, and intensifying Hepatitis B vaccination of high risk groups are exactly essential for better health planning and an appropriate implementation of them will further decrease the HBV infection rate in general population. In conclusion, our results indicate that an appropriate implementation of IBTO programs such as the selection of blood donors/ donor recruitment, increasing non-remunerated repeat donors, routine screening for blood borne viruses, replacement donation exclusion, and implementation of automation are being performed.

**Acknowledgment**

We would like thank all participants of this survey. Also, we gratefully acknowledge to Blood Transfusion Research center, High Institute for Research and Education in Transfusion Medicine for initiating and encouraging this program of research.

**References**

Decline of Hepatitis B virus in Iranian Blood Donors …